Nathan Shock Center of Excellence The NIA-supported Einstein Nathan Shock Center (E-NSC) represents a collection of nearly 80 internal and external faculty actively engaged in high-impact science and collaborations in the biology of aging, three innovative, state-of-the-art Research Resource Cores, and extensive opportunities for enrichment and training in aging research. The Nathan Shock Center is structured aroundfour research cores Proteostasis of Aging Protein quality control maintenance and homeostasis Director: Ana Maria Cuervo, M.D. Ph.D. Learn More Health Span Physiologic phenotyping through lifespan Director: Derek Huffman, Ph.D. Learn More Human Multi-omics Data Human high-throughput omics data sharing and technical advising Directors: Jan Vijg, Ph.D. and Nir Barzilai, M.D. Learn More Research Development Ensuring the future of Biology of Aging through mentoring, P&F funding, and education Directors: Rajat Singh, M.B.B.S. and Sofiya Milman, M.D. Learn More Training Einstein's Institute for Aging Research is committed to the development the next generation scientists in the biology of aging. Training programs are available for graduate and postdoctoral candidates. Learn More Publications See More Misfolded GBA/β-glucocerebrosidase impairs ER-quality control by chaperone-mediated autophagy in Parkinson diseaseThe immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity developmentResilience to aging is a heterogeneous characteristic defined by physical stressorsQuality Control: Maintaining molecular order and preventing cellular chaosHeterochronic parabiosis: a valuable tool to investigate cellular senescence and other hallmarks of agingMicroglial NF-κB drives tau spreading and toxicity in a mouse model of tauopathySingle-cell analysis of somatic mutations in human bronchial epithelial cells in relation to aging and smokingSingle-molecule, quantitative detection of low-abundance somatic mutations by high-throughput sequencingProtective role of chaperone-mediated autophagy against atherosclerosisGeroscience-guided repurposing of FDA-approved drugs to target aging: A proposed process and prioritization